title: Comment on "Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion".
authors.affiliation: Pharmaceutical Development and ‡Pharmacokinetics and Drug Disposition, Allergan Inc , 2525 Dupont Drive, Irvine, California 92612, United States.
authors.forename: Anuradha
authors.initials: A
authors.lastname: Gore
authors.forename: Mayssa
authors.initials: M
authors.lastname: Attar
authors.forename: Chetan
authors.initials: C
authors.lastname: Pujara
authors.forename: Sesha
authors.initials: S
authors.lastname: Neervannan
mesh_terms: D016572:Cyclosporine / Q000737:chemistry*; D016503:Drug Delivery Systems; D004655:Emulsions; D006801:Humans; D007166:Immunosuppressive Agents / Q000737:chemistry*; D009883:Ophthalmic Solutions / Q000737:chemistry*; D011786:Quality Control; D013678:Technology, Pharmaceutical / Q000592:standards*
chemical_list: D004655:Emulsions; D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016572:Cyclosporine